the Dense result was positive however like any other study. it...

the Dense result was positive however like any other study. it do not constitute money in the door.

However, it does provide a licence to hunt, particularly in Europe.

The next announcement of interest will be the FDA and the release of national standards in the US. It should be remembered that a majority of US states already mandate some degree of reporting of breast density, however the requirements vary across states.

the drivers of growth in the VHT business have not changed in the US they remain:-

1) hitting the 27% target and increasing coverage over time- this may also include further acquisitions.

2) increasing the ARR - this has the potential to be the game changer - if fee per service can be increased from currently just over 1$ us to 10$ us , it will make VHT very profitable business. The ability to increase this fee will be the integration of the VHT business with the US business and repackaging as a new product (ie1+1=3) . This repackaging provides the opportunity to reprice upwards.

3) Whilst the focus has been on the US, the Dense result will influence change particularly in Europe and will hopefully result in growth of their business there.

if management can execute successfully, I expect this stock to double in value in the next 3to4 years.

However, like any other stock it will go up and down over this period - it is never a straight line up.

best of luck to all

RegardS